Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Ali Akram Khan

Interventional Cardiology Flint, MI Medical Doctor

NPI 1356873012 CMS profile 7224793

G3230 Beecher Rd Ste 1, Flint, MI 48532

Open in the dashboard

General payments

$23,404

122 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ali Akram Khan of Flint, MI is reported in the CMS Open Payments database as having received $23,404 across 122 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $14,573 31
2024 General $5,853 57
2023 General $2,075 22
2022 General $624 9
2021 General $280 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ali Akram Khan
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Ali Akram Khan were reported at $14,573. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Ali Akram Khan Interventional Cardiology median Middle half National median
2019 $0 $1,097 $329–$3,048 $163
2020 $0 $473 $161–$1,480 $114
2021 $280 $677 $233–$1,827 $132
2022 $624 $978 $333–$2,724 $149
2023 $2,075 $1,136 $382–$2,986 $160
2024 $5,853 $1,181 $395–$3,326 $164
2025 $14,573 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Medtronic, Inc. $11,116 16 payments
  2. Inari Medical, Inc. $2,555 18 payments
  3. Abiomed $2,287 24 payments
  4. Penumbra, Inc. $1,938 7 payments
  5. Philips Electronics North America Corporation $1,682 5 payments
  6. Abbott Laboratories $678 7 payments
  7. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $660 13 payments
  8. Boston Scientific Corporation $654 6 payments
  9. Pfizer Inc. $307 3 payments
  10. Kestra Medical Technology Services, Inc. $215 4 payments
  11. Other $1,314 19 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Grant $10,000 1 payment
  2. Food and Beverage $7,724 105 payments
  3. Travel and Lodging $5,221 11 payments
  4. Education $459 5 payments
Products named General payments · program years 2021–2025
  1. CT THROMBECTOMY SYSTEM KIT $2,555 18 payments
  2. FLOWTRIEVER CATHETER, S $2,555 18 payments
  3. Indigo System $1,938 7 payments
  4. Impella $1,902 18 payments
  5. IGT Devices Undivided $1,644 4 payments
  6. LifeVest $660 13 payments
  7. Micra $513 4 payments
  8. COREVALVE EVOLUT R $419 7 payments
  9. VYNDAQEL $307 3 payments
  10. Assure WCD $215 4 payments
  11. Other $2,519 34 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

55

Median for Interventional Cardiology: 2,236

Drug cost

$1,001

Median for Interventional Cardiology: $380,412

Branded share of claims

0%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rosuvastatin Calcium Generic 16 $402
Metoprolol Succinate Generic 18 $360
Losartan Potassium Generic 21 $239

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VYNDAQEL
  • PFIZER INC. $182
$182 — —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $99
$99 — —
KENGREAL
  • CHIESI USA, INC. $70
$70 — —
WAINUA
  • AstraZeneca Pharmaceuticals LP $26
$26 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

122 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record